Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31181951 | 1.00 | RAB9A (0.50) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL1174412 | 0.95 | RAB9A (0.49) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL14498916 | 0.81 | KDR (0.47) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL5138986 | 0.77 | SIGMAR1 (0.51) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL10510232 | 0.77 | RAB9A (0.47) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL5584876 | 0.76 | RAB9A (0.46) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL17384805 | 0.76 | RAB9A (0.46) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL29208556 | 0.75 | RAB9A (0.49) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL374022 | 0.74 | RAB9A (0.74) | RAB9ANPC1KDM4EMAPTMEN1 | |
| SCHEMBL29631691 | 0.74 | RAB9A (0.74) | RAB9ANPC1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716493-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2066324-B1 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | CEPHALON, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| CN-101560213-B | Polycyclic compound functioned as inhibitor of enzyme parp, vegfr2 and mlk3 and the application | CEPHALON INC | 2011-01-19 | — | — | CN | disclosed |
| EP-2050750-B1 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON INC (US) | 2010-09-22 | — | — | EP | disclosed |
| CN-100554268-C | Polycyclic compounds as inhibitors of PARP, VEGFR2 and MLK3 enzymes and uses | CEPHALON INC (US) | 2009-10-28 | — | — | CN | disclosed |
| CN-101560213-A | Polycyclic compound functioned as inhibitor of enzyme parp, vegfr2 and mlk3 and the application | CEPHALON INC (US) | 2009-10-21 | — | — | CN | disclosed |
| CN-101500563-A | Cycloalkanopyrolocarbazole derivatives and the use thereof as PARP, VEGFR2 and MLK3 inhibitors | CEPHALON INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2066324-A2 | CYCLOALKANOPYROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2050750-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007149451-A2 | CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS | CEPHALON, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| EP-1754707-A2 | Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | CEPHALON, INC. (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-12-07 | — | — | US | disclosed |
| US-7122679-B2 | Multicyclic compounds and the use thereof | CEPHALON, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1294725-B1 | MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON INC (US) | 2006-01-04 | — | — | EP | disclosed |
| CN-1440409-A | Polycyclic compounds as inhibitors of PARP, VEGFR2 and MLK3 enzymes and uses | CEPHALON INC (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1294725-A2 | MULTICYCLIC COMPOUNDS AND THE USE THEREOF AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | CEPHALON, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001085686-A2 | MULTICYCLIC COMPOUNDS AND THE USE AS INHIBITORS OF PARP, VEGFR2 AND MLK3 ENZYMES | CEPHALON, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276497-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | RAB9A 4431/4885NPC1 4396/4885KDM4E 2445/4885 |
| US-20020028815-A1 | Novel multicyclic compounds and the use thereof | MLKL, PARP3, PARP1 | RAB9A 4431/4885NPC1 4396/4885KDM4E 2445/4885 |
| US-20110059959-A1 | NOVEL MULTICYCLIC COMPOUNDS AND THE USE THEREOF | MLKL, PARP3, PARP1 | RAB9A 4431/4885NPC1 4396/4885KDM4E 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.